SYRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Spyre Therapeutics Inc (SYRE) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. Despite the pre-market price dip, the company's strong pipeline, positive analyst ratings, institutional confidence, and long-term growth potential make it a compelling investment opportunity.
The stock shows a bullish trend with moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram of 0.894. RSI is neutral at 74.607, and the stock is trading near its resistance level (R1: 44.422).
Commodore Capital increased its stake in SYRE by $10.46 million, reflecting institutional confidence.
The company has $757 million in cash, sufficient to fund R&D into
Analysts project significant sales growth and have issued high price targets ($53-$64).
The stock has outperformed the S&P 500 with a 62.9% gain over the past year.
Pre-market price decline of -0.95%.
No recent congress trading data or significant insider/hedge fund activity.
Financials show negative EPS (-0.
and net income (-$62.53M), although improving YoY.
In Q4 2025, revenue remained at $0, net income improved by 11.07% YoY to -$62.53M, and EPS dropped by -18.63% YoY to -0.83. The company has a strong cash position of $757M to support R&D through 2028.
Mizuho and Citi initiated coverage with Outperform and Buy ratings, respectively, and price targets of $53 and $64. Analysts highlight the company's strong pipeline and potential in autoimmune and inflammatory diseases, projecting risk-adjusted sales of $1.7B by 2035.
